http://www.neurenpharma.com//irm/sh...unceGuid=3992c756-6537-47c3-92ee-06a33bbfcee9
Damn.
The trial did not demonstrate a difference between drug and placebo in the 3 core efficacy measures, which were the Extended Glasgow Outcome Scale (GOS-E), the Mayo-Portland Adaptability Inventory (MPAI-4) and mortality.
The overall rate of mortality in the INTREPID trial was lower than was observed in prior trials, but there was no significant difference between drug and placebo.
Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |